Search

Your search keyword '"Windhövel, Ute"' showing total 14 results
Start Over Author "Windhövel, Ute"
14 results on '"Windhövel, Ute"'

1. Guideline adherence in the use of coronary angiography in patients presenting at the emergency department without myocardial infarction – Results from the German ENLIGHT-KHK project

Author

Wein, Bastian, Seleznova, Yana, Mueller, Dirk, Naumann, Marie, Loeser, Simon, Steffen, Melanie, Windhoevel, Ute, Haude, Michael, vom Dahl, Juergen, Schaefer, Ulrich, Montenbruck, Moritz, Jegodka, Ruediger, Dill, Thorsten, Guelker, Jan-Erik, Boese, Dirk, Bogs, Björn, Harmel, Eva, and Bruder, Oliver

Published
2023
Full Text
View/download PDF

2. Evaluation of Guideline Adherence for Cardiac Catheterization in Patients With Presumed Obstructive Coronary Artery Disease in Germany (ENLIGHT-KHK) – A Multicentre, Prospective, Observational Study

Author

Seleznova, Yana, primary, Wein, Bastian, additional, Müller, Dirk, additional, Naumann, Marie, additional, Bruder, Oliver, additional, Steffen, Melanie, additional, Windhövel, Ute, additional, Loeser, Simon, additional, Artmann, Jörg, additional, Fritz, Thomas, additional, Eckardt, Melanie, additional, Stock, Stephanie, additional, and Naber, Christoph Kurt, additional

Published
2021
Full Text
View/download PDF

6. Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents

Author

Garot, Philippe, Morice, Marie-Claude, Tresukosol, Damras, Pocock, Stuart J, Meredith, Ian T, Abizaid, Alexandre, Carrié, Didier, Naber, Christoph, Iñiguez, Andres, Talwar, Suneel, Menown, Ian B A, Christiansen, Evald H, Gregson, John, Copt, Samuel, Hovasse, Thomas, Lurz, Philipp, Maillard, Luc, Krackhardt, Florian, Ong, Paul, Byrne, Jonathan, Redwood, Simon, Windhövel, Ute, Greene, Samantha, Stoll, Hans-Peter, and Urban, Philip

Subjects
drug-coated stent, DAPT, bare-metal stent, bleeding, Cardiology and Cardiovascular Medicine, thrombosis
Abstract

BACKGROUND: For patients at high risk for bleeding, a polymer-free metallic stent coated with biolimus-A9 followed by one-month dual antiplatelet therapy was safer and more effective than a bare metal stent at one year.OBJECTIVES: Longer-term follow-up is needed to determine whether these benefits are maintained.METHODS: In a prospective, multi-center, double blind trial, we randomly assigned 2466 high bleeding risk patients to receive a drug coated stent (DCS) or a bare metal stent (BMS) followed by one month dual antiplatelet therapy and 98.1% completed a two-year follow-up. The primary safety end point was a composite of cardiac death, myocardial infarction (MI), or stent thrombosis (ST). The primary efficacy end point was clinically driven target-lesion revascularization.RESULTS: At 2 years, the primary safety endpoint had occurred in 147 DCS (12.6%) and 180 BMS patients (15.3%) (hazard ratio 0.80; 95% CI, 0.64 to 0.99; p=0.039). Clinically driven target-lesion revascularization occurred for 77 DCS (6.8%) and 136 BMS patients (12.0%) (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P 75, anemia, raised plasma creatinine and planned long-term anticoagulation. Correlates of the primary safety endpoint were age anemia, congestive heart failure, multivessel disease, number of stents implanted and use of a BMS rather than a DCS.CONCLUSIONS: The safety and efficacy benefits of DCS over BMS were maintained up to two years in high bleeding risk patients. During that period, overall rates of major bleeding and coronary thrombotic events were no different and associated with a substantial and comparable mortality risk.

Published
2016
Full Text
View/download PDF

7. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents

Author

Garot, Philippe, primary, Morice, Marie-Claude, additional, Tresukosol, Damras, additional, Pocock, Stuart J., additional, Meredith, Ian T., additional, Abizaid, Alexandre, additional, Carrié, Didier, additional, Naber, Christoph, additional, Iñiguez, Andres, additional, Talwar, Suneel, additional, Menown, Ian B.A., additional, Christiansen, Evald H., additional, Gregson, John, additional, Copt, Samuel, additional, Hovasse, Thomas, additional, Lurz, Philipp, additional, Maillard, Luc, additional, Krackhardt, Florian, additional, Ong, Paul, additional, Byrne, Jonathan, additional, Redwood, Simon, additional, Windhövel, Ute, additional, Greene, Samantha, additional, Stoll, Hans-Peter, additional, Urban, Philip, additional, and Abizaid, Alexander, additional

Published
2017
Full Text
View/download PDF

13. Effect of cyclooxygenase-2 antisense oligodeoxyribonucleotides in A-549 lung cancer cells.

Author

Windhövel U, Haasper C, Duchrow M, Bruch HP, and Broll R

Subjects
Adenocarcinoma enzymology, Cell Growth Processes genetics, Cell Line, Tumor, Cyclooxygenase 2, Flow Cytometry, Genetic Therapy, Humans, Lung Neoplasms enzymology, Membrane Proteins, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Transfection, Adenocarcinoma genetics, Adenocarcinoma therapy, Lung Neoplasms genetics, Lung Neoplasms therapy, Oligodeoxyribonucleotides, Antisense genetics, Prostaglandin-Endoperoxide Synthases genetics
Abstract

Background: Cyclooxygenase (COX)-2 is overexpressed in several tumor entities and seems to play a key role in carcinogenesis. This makes it a potential target in cancer therapy., Materials and Methods: Twelve phosphorothioate-modified antisense oligonucleotides (asODNs) against six targets of COX-2 mRNA were transfected to A-549 lung carcinoma cells. COX-2 mRNA and protein levels were determined by quantitative RT-PCR and flow cytometry, respectively. Cell growth was assessed by measuring Alamar Blue reduction., Results: The tested asODNs exhibited a range of activities. The most potent asODN reduced uninduced COX-2 mRNA to 66% and protein level to 75%, respectively. While this asODN did not influence cell growth, a 15% growth reduction was observed after transfection of another asODN which suppressed COX-2 mRNA to 71% and protein level to 84%., Conclusion: The use of asODNs directed against COX-2 mRNA is a promising approach to inhibit COX-2 expression in tumor cells.

Published
2004

14. Bansformation of tobacco with a mutated cyanobacterial phytoene desaturase gene confers resistance to bleaching herbicides.

Author

Wagner T, Windhövel U, and Römer S

Subjects
Chlorophyll metabolism, Crosses, Genetic, Cyanobacteria enzymology, Oxidation-Reduction, Oxidoreductases metabolism, Plants, Genetically Modified drug effects, Plants, Genetically Modified enzymology, Recombinant Proteins metabolism, Nicotiana drug effects, Nicotiana enzymology, Carotenoids metabolism, Cyanobacteria genetics, Herbicides pharmacology, Insecticide Resistance genetics, Oxidoreductases genetics, Nicotiana genetics
Abstract

Carotenoids are constituents of the photosynthetic apparatus and essential for plant survival because of their involvement in protection of chlorophylls against photooxidation. Certain classes of herbicides are interfering with carotenoid biosynthesis leading to pigment destruction and a bleached plant phenotype. One important target site for bleaching herbicides is the enzyme phytoene desaturase catalysing the desaturation of phytoene in zeta-carotene. This enzymatic reaction can be inhibited by norflurazon or fluridone. We have transformed tobacco with a mutated cyanobacterial phytoene desaturase gene (pds) derived from the Synechococcus PCC 7942 mutant NFZ4. Characterization of the resulting transformants revealed an up to 58 fold higher norflurazon resistance in comparison to wild type controls. The tolerance for fluridone was also increased 3 fold in the transgenics. Furthermore, the transformed tobacco maintained a higher level of D1 protein of photosystem II indicating a lower susceptibility to photooxidative damage in the presence of norflurazon. In contrast, the genetic manipulation did not confer herbicide resistance against zeta-carotene desaturase inhibitors.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results